ID   U-2973
AC   CVCL_1898
DR   BioSample; SAMN03473456
DR   ChEMBL-Cells; CHEMBL4523524
DR   ChEMBL-Targets; CHEMBL4523555
DR   DSMZ; ACC-642
DR   DSMZCellDive; ACC-642
DR   PubChem_Cell_line; CVCL_1898
DR   Wikidata; Q54973563
RX   PubMed=18510704;
RX   PubMed=23171647;
RX   PubMed=26727417;
CC   Doubling time: ~35 hours (DSMZ=ACC-642).
CC   Sequence variation: Gene fusion; HGNC; HGNC:990; BCL2 + HGNC; HGNC:5477; IGH; Name(s)=IGH-BCL2 (PubMed=18510704).
CC   Sequence variation: Gene fusion; HGNC; HGNC:6690; IRAG2 + HGNC; HGNC:7553; MYC; Name(s)=MYC-IRAG2, MYC-LRMP (PubMed=23171647).
CC   Omics: Genome sequenced.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ=ACC-642
ST   Amelogenin: X,Y
ST   CSF1PO: 11
ST   D13S317: 10,11
ST   D16S539: 11,13
ST   D18S51: 12,16
ST   D19S433: 13,14
ST   D21S11: 29,32.2
ST   D2S1338: 23,24
ST   D3S1358: 15,18
ST   D5S818: 11,12
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 21,22
ST   Penta D: 12,13
ST   Penta E: 16
ST   TH01: 7,9.3
ST   TPOX: 8
ST   vWA: 17,20
DI   NCIt; C125904; High grade B-cell lymphoma with MYC and BCL2 or BCL6 rearrangements
DI   ORDO; Orphanet_480541; High grade B-cell lymphoma with MYC and/or BCL2 and/or BCL6 rearrangement
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 19-12-24; Version: 23
//
RX   PubMed=18510704; DOI=10.1111/j.1600-0609.2008.01098.x;
RA   Bostrom H., Leuchowius K.-J., Hallbook H., Nordgren A., Thorn I.,
RA   Thorselius M., Rosenquist R., Soderberg O., Sundstrom C.;
RT   "U-2973, a novel B-cell line established from a patient with a mature
RT   B-cell leukemia displaying concurrent t(14;18) and MYC translocation
RT   to a non-IG gene partner.";
RL   Eur. J. Haematol. 81:218-225(2008).
//
RX   PubMed=23171647; DOI=10.1186/1756-0500-5-648; PMCID=PMC3534606;
RA   Hooper S.D., Jiao X., Sundstrom E., Rehman F.L., Tellgren-Roth C.,
RA   Sjoblom T., Cavelier L.;
RT   "Sequence based analysis of U-2973, a cell line established from a
RT   double-hit B-cell lymphoma with concurrent MYC and BCL2
RT   rearrangements.";
RL   BMC Res. Notes 5:648.1-648.4(2012).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//